HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 10-27-2013, 09:33 AM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post The challenge of reporting dense breasts

Public release date: 10-Sep-2013
[ Print | E-mail Share ] [ Close Window ]

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Experts take on challenge of breast density notification laws

OAK BROOK, Ill. – A team of California-based breast imagers and breast cancer risk specialists have developed a website to help navigate the new challenges posed by breast density notification laws, according to a special report published online in the journal Radiology.
While mammography is considered the best single modality for population-based screening, its sensitivity is diminished by up to 20 percent in patients with dense breasts (breasts with a higher ratio of fibroglandular tissue to fat). This reduction in sensitivity is due for the most part to masking, a phenomenon in which surrounding dense breast tissue obscures a cancer on mammography.
In response, several states have adopted laws requiring patient and referring physician notification when the interpreting radiologist determines that the pattern of fibroglandular tissue on a patient's mammogram is considered dense.
In California, mandatory reporting requirements took effect on April 1, 2013. The law requires that patients with dense breast tissue on screening mammography receive notification in writing, with advice on discussing their screening options with their primary physician.
"The legislation was prompted by breast cancer advocacy groups motivated to educate women regarding the limitations of mammography," said Jafi A. Lipson, M.D., assistant professor of radiology at Stanford University School of Medicine in Stanford, Calif.
The California law has potentially enormous implications, as approximately 50 percent of women undergoing screening mammography are classified as having either "heterogeneously dense" or "extremely dense" breasts. For California alone, this could mean two million notification letters a year, and a significant increase in supplementary screening with MRI and ultrasound.
The broad classification of breast density under California law does not take into account the varying risk levels among patients with different breast densities. When risk is expressed relative to average breast density, the risk for the 40 percent of women with heterogeneously dense breasts is about 1.2 times greater than average and the risk for the 10 percent of women with extremely dense breasts is about 2.1times greater than average. Therefore, breast density is a risk factor, but not a strong one.
"While additional screening for women with extremely dense breasts could prove beneficial, supplemental screening of the approximately 40 percent of California women with heterogeneously dense breasts would result in very substantial additional cost to the healthcare system," Dr. Lipson said. "There also is concern that the increased use of supplementary screening will ultimately expose some patients to more harm, in the form of false-positive results, than good."
To help address these challenges, Dr. Lipson and colleagues in the California Breast Density Information Group (CBDIG) created an online document to answer frequently asked questions about the efficacy, benefits and harms of supplementary screening tests.
"Increased patient awareness may be considered a benefit, although there are also potential harms of notification, including awareness without a clear path forward for women and care providers, increased unsubstantiated anxiety, potential for misunderstanding or overestimation of density-associated risk and increased propensity to over-screen," Dr. Lipson said.
CBDIG recommends an individualized risk-based approach for guiding the decision-making process. Women with a high risk of breast cancer, such as those with the BRCA genetic mutation, are more likely to benefit from additional screening with MRI or ultrasound, or with tomosynthesis—a promising supplementary screening technology. For women with intermediate risk, the decision to have a screening MRI should be made on a case-by-case basis using a shared decision-making approach.
The benefits of additional screening are diminished in women who are not high risk, while the potential harms remain the same.
"Studies show a small number of added cancers are found with supplementary screening breast ultrasound," Dr. Lipson said. "However, this is at the price of a large number of benign breast biopsies."
The CBDIG researchers suggested that women who request supplementary breast screening may be rapidly triaged for assessment based on their individual risk factors.
Insurance coverage is likely to have a major impact on supplementary breast imaging. The California legislature did not mandate insurance coverage for any supplementary breast cancer screening tests, and there are no insurance billing codes for screening breast ultrasound or tomosynthesis. Only one state has a notification law and an insurance mandate, so many women who desire certain types of supplementary screening may be asked to pay out of pocket.
###
The CBDIG document is available online at http://www.breastdensity.info.
"The California Breast Density Information Group: A Collaborative Response to the Issues of Breast Density, Breast Cancer Risk, and Breast Density Notification Legislation." Collaborating with Dr. Lipson were Elissa R. Price, M.D., Jonathan Hargreaves, M.D., Edward A. Sickles, M.D., R. James Brenner, M.D., J.D., Karen K. Lindfors, M.D., M.P.H., Bonnie N. Joe, M.D., Ph.D., Jessica W. T. Leung, M.D., Stephen A. Feig, M.D., Lawrence W. Bassett, M.D., Haydee Ojeda-Fournier, M.D., Bruce L. Daniel, M.D., Allison W. Kurian, M.D., M.Sc., Elyse Love, M.S., C.G.C., Lauren Ryan, M.S., L.C.G.C., Donna D. Walgenbach, M.S., C.G.C., and Debra M. Ikeda, M.D.
Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc.
RSNA is an association of more than 51,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Ill. (RSNA.org)
For patient-friendly information on breast imaging, visit RadiologyInfo.org.
'lizbeth is offline   Reply With Quote
Old 10-27-2013, 04:20 PM   #2
jacqueline1102
Senior Member
 
Join Date: Apr 2012
Posts: 183
Re: The challenge of reporting dense breasts

Please see previous posts by me regarding dense breasts. Hopefully, it will be helpful.

Take care,

Jackie
__________________
10/11 IBC Stage IV; 1 liver met 4.6 cm.
10/11-2/12 TCH for 6 rounds
3/12 Right MRM
5/12-7/12 33 Radiation treatments
8/1/12 Started Perjeta along with the Herceptin
10/12 Scans said NED for first time
5/15 UWSeattle Vaccine Trial 3 months
12/16 Scans still show NED. Herceptin and Perjeta continue indef.
8/17 Taken off Perjeta;staying on Herceptin. Still NEAD.
3/18 Still NEAD
8/19 Now on Subcutaneous Herceptin
10/21 Remain on Subcutaneous Herceptin (Hylecta)
11/21 CT showed possible lung mets. Was told to wait and see until scan
1/22 CT shows continued growth
03/22 Lung Biopsy said sample was too small but nodules keep growing and IR is convinced that it is indeed cancer
04/22 Oncologist referred for consult for a transbronchial biopsy. This does not sound pleasant
jacqueline1102 is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 02:52 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter